SYRE — Spyre Therapeutics Share News
0.000.00%
Last trade - 00:00Spyre Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Spyre Therapeutics Q2 loss narrower than expected; sees trial readouts in 2026
Brief: Spyre Therapeutics Files For Mixed Shelf Size Not Disclosed - Filing
Spyre says bowel disease drug cuts inflammation in mid-stage trial
Spyre Therapeutics posts wider-than-expected Q1 net loss
U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems
U.S. STOCKS ON THE MOVE-Nike, PNC Financial, Papa John's
Spyre Therapeutics gains after boosted $403 mln stock sale
Brief: Spyre Therapeutics Announces Pricing Of Upsized $403 Million Public Offering Of Common Stock
Spyre drops on equity offering launch following inflammatory bowel drug trial
Brief: Spyre Therapeutics Announces Proposed Public Offering Of Its Common Stock
Brief: Spyre Therapeutics Inc - Suspends And Terminates ATM Prospectus For At-The-Market Offering Effective April 13, 2026 - SEC Filing
U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma
Spyre rises after bowel disease drug succeeds in mid-stage study
Spyre's inflammatory bowel drug shown to reduce disease activity in mid-stage study (updated)
Spyre rises after bowel disease drug succeeds mid-stage study
NASDAQ RESUMED AT 07:25 AM
NASDAQ TRADE HALT NEWS AND RESUMPTION TIMES AT 07:25 AM